alexa Fazlul H. Sarkar | OMICS International
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Fazlul H. Sarkar

Fazlul H. Sarkar Fazlul H. Sarkar
Wayne State School of Medicine
Detroit, MI 48201,USA
Tel: 3135768327


Dr. Sarkar is currently a Distinguished Professor in the Departments of Pathology and Oncology at Karmanos Cancer Institute, Wayne State University School of Medicine who started his scientific career in 1978 when he completed his Ph.D. thesis work. Dr. Sarkar’s early research, which still continues, is focused on understanding the role of a “master” transcription factor, NF-B, and the regulation of its upstream and downstream signaling molecules in solid tumors, and focusing on tumor microenvironment. Moreover, his research has been directed toward elucidating the molecular mechanism(s) of action of “natural agents”, their synthetic analogues, and other synthetic small molecule inhibitors of Bcl-2 and MDM2 for cancer prevention and therapy. The discoveries from in vitro and in vivo preclinical studies led to the design and execution of multiple Phase I/II clinical trials in breast, pancreas and prostate cancer for assessing the effects of several “natural agents” in the alterations of biomarkers as well as some early clinical efficacy testing. Dr. Sarkar’s research led to the concept of chemo-sensitization of cancer cells by reversing their drug-resistance phenotype to conventional therapeutics (chemo-radio-therapy), and all of which has been focused on tumor microenvironment, system biology and integrated holistic approach which led to clinical trials conducted at the Karmanos Cancer Institute. The innovation of his basic science research has attracted clinicians to collaborate with him, which clearly documents his leadership in translational research. Dr. Sarkar’s recent research in the last 15 years has also been focused on understanding the molecular mechanism(s) of Epithelial-to-Mesenchymal Transition (EMT), a phenomenon that is reminiscent of cancer stem cells (CSCs) or cancer stem-like cells (CSLCs) within the tumor microenvironment, which are highly resistant to conventional therapeutics. Since understanding the molecular mechanism(s) only is not sufficient, his research also extended to the discovery of strategies by which drug-resistant EMT phenotypic cells (CSCs or CSLCs) could be eliminated by novel agents including “natural agents” (Two patents pending on this topic). Dr. Sarkar also discovered early-on that targeting microRNAs (miRNAs) by such agents could become a newer avenues for the treatment of human malignancies. The application of systems biology in elucidating the targets of specific miRNAs and their role in developing novel targeted therapeutic agents is his primary focus in recent years for translational research. It is important to note that his pre-clinical and ongoing clinical studies using BR-DIM is a perfect example of “bench to bedside” research. Moreover, Dr. Sarkar have recently developed a novel synthetic derivative of a “natural agent”-curcumin, named as CDF (3.4-difluorobenozo-curcumin or in short difluorinated curcumin), which is currently being planned for toxicological testing for clinical development. Dr. Sarkar has been collaborating with many investigators focusing on tumor microenvironment and developing strategies for conditioning the tumor microenvironment in different tumor models in order to optimize therapeutics. Dr. Sarkar has over 30 years of molecular cancer research expertise and he is also an experts in “bench-to-bedside” as well as “bedside-to-bench” (clinical translational research). Overall, his expertise would be instrumental in developing multi-faceted molecular and translational cancer research program that could be coupled with drug discovery and development for the treatment of human malignancies. Dr. Sarkar trained numerous pre-doctoral and post-doctoral students throughout the last 25 years at Wayne State University. In addition, he served and still serving on a number of departmental, university and national committees, and continue to serve in both NIH and DOD study sections including NIH program projects, SPORE grants and Cancer Center Core grants (site visit) for NCI-designated Comprehensive Cancer Centers. Currently, Dr. Sarkar is the chair of the Promotion & Tenure Committee of the Department of Pathology, which requires leadership skills. Moreover, Dr. Sarkar is a member of the editorial board of many cancer-specific and medicinal chemistry related journals. In summary, the above accomplishments clearly provide broader perspectives on Dr. Sarkar’s expertise in the field of cancer biology, cancer drug discovery, experimental therapeutics, medicinal chemistry, molecular mechanism of tumor aggressiveness within the tumor microenvironment, pre-clinical model research and conducting clinical trials. In addition, his experience is worth noticing in leading basic and clinical scientists to translate discoveries to early phase investigator-initiated clinical trials. Lastly, Dr. Sarkar’s activities clearly document his leadership expertise, and he really earned his well-deserved national and international stature in cancer research and drug discovery specifically focusing on conditioning the tumor microenvironment. Based on Dr. Sarkar’s accomplishments, he has been inducted to the “Academy of Scholars” at Wayne State University in 2012.

Research Interest

Molecular mechanism(s) of Epithelial-to-Mesenchymal Transition (EMT)


Differential Expression of MicroRNAs in Papillary Thyroid Carcinoma and Their Role in Racial Disparity

Raagini Suresh, Seema Sethi, Shadan Ali, Tamar Giorgadze and Fazlul H. Sarkar

Research Article: J Cancer Sci Ther/Vol.7.5 145-154 (2015)

DOI: 10.4172/1948-5956.1000340

Lung Cancer Stem Cells: Current Progress and Future Perspectives

Rasha Salama, Joy Tang, Shirish M. Gadgeel, Aamir Ahmad and Fazlul H. Sarkar

Review Article: J Stem Cell Res Ther 2012, S7-007

DOI: 10.4172/2157-7633.S7-007

Global Speakers in the subject

Global Experts in the subject

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7